The FDA has approved Aggrenox (aspirin/extended-release dipyridamole) 25 mg/200 mg capsules dosed twice daily for the prevention of stroke in patients who have experienced a previous stroke or a transient ischemic attack. The FDA approval was based on the results of the European Stroke Prevention Study 2, the largest recurrent stroke prevention trial ever conducted. Results from ESPS2 indicated that Aggrenox reduces the risk of recurrent stroke by 37 percent compared with a placebo. The study also showed that Aggrenox, which is manufactured by Boehringer Ingelheim, reduces the risk of recurrent stroke by 22 percent over aspirin (50 mg/day) alone.
COPYRIGHT 1999 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group